All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Orphan drug designation granted to PCLX-001 by the FDA
On October 14, 2022, PCLX-001, a first-in-class, oral, small-molecule N-myristoylation inhibitor currently in clinical development, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia (AML).1
PCLX-001 has shown positive results in animal models of AML and in AML patient-derived xenografts, where PCLX-001 treatment reduced human peripheral blood and bone marrow CD45+ cells by up to 95%.1
PCLX-001 is currently being evaluated in a phase I trial in patients with non-Hodgkin lymphoma and solid tumors in Canada (NCT04836195). An investigational new drug application has been filed to study PCLX-001 in patients with AML in the United States.1
- Pacylex announces orphan drug designation granted to PCLX-001 for the treatment of acute myeloid leukemia https://pacylex.reportablenews.com/pr/pacylex-announces-orphan-drug-designation-granted-to-pclx-001-for-the-treatment-of-acute-myeloid-leukemia Published Oct 14, 2022. Accessed Oct 17, 2022.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox